A5015363346- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Liver Disease Diagnosis and Treatment
- Pharmaceutical Economics and Policy
- Peptidase Inhibition and Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Potato Plant Research
- Acute Myeloid Leukemia Research
- Ethics and bioethics in healthcare
- Angiogenesis and VEGF in Cancer
- Cell death mechanisms and regulation
- Ultrasound and Hyperthermia Applications
- Neutropenia and Cancer Infections
- Global Cancer Incidence and Screening
- Public Health in Brazil
- Bacterial Identification and Susceptibility Testing
- History of Medicine and Tropical Health
- Pharmaceutical studies and practices
Mylan (United States)
2021-2024
Novartis (Mexico)
2012-2013
Hospital Angeles Pedregal
2011
Instituto Nacional de Cancerología
2005
Ankara University
2002
Nottingham City Hospital
2002
Centre Oscar Lambret
2002
Klinikum Mutterhaus der Borromäerinnen
2002
Abstract Purpose: Pathologic angiogenesis has been correlated with tumor growth, dissemination, metastasis, and prognosis in solid tumors including breast cancer. Angiogenesis also implicated the pathophysiology of, shown to be a therapeutic target arising bone marrow. The status of marrow cancer patients is unknown. aim this study was estimate extent subset patients. Experimental Design: We studied 42 women whom biopsy done. Bone samples were sorted according their infiltration by cells. In...
To investigate the cost-efficiency and budget-neutral expanded access of biosimilar intravenous trastuzumab-dkst versus reference (trastuzumab-IV) subcutaneous trastuzumab (trastuzumab-SC) (with/without pertuzumab) in metastatic breast cancer (MBC).Economic simulation modeling a panel 1,000 MBC patients to estimate: 1) cost-savings by conversion from trastuzumab-IV or trastuzumab-SC at 10-100% rates 3 weight groups: first quartile (Q1:62.2 kg), median (73.1 third (Q3:88.6 2) cost-savings.In...
Abstract Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared originator trastuzumab combined taxane followed monotherapy in patients HER2-positive metastatic breast cancer (MBC). Herein, we present final (OS) from HERITAGE. Methods a multicenter, double-blind, randomized, parallel-group study. Patients were randomized 1:1 to receive...
Abstract Purpose: In biopsies of patients with locally advanced breast cancer, we investigated the in vivo changes gene expression pattern induced by chemotherapy to find genes that are potentially responsible for efficacy drug. Experimental Design: Early cellular responses chemotherapy-induced damage, both and vitro, were analyzing profiles. Core taken from nine before at 6 hours after initiation doxorubicin-based chemotherapy. Both samples cohybridized on same microarray containing 18,000...
Background and objectives Correct identification of estrogen receptor (ER) status in breast cancer (BC) is crucial to optimize treatment; however, standard care, involving biopsy immunohistochemistry (IHC), other diagnostic tools such as 2-deoxy-2-[ 18 F]fluoro-D-glucose or 2-[ F]fluoro-2-deoxy-D-glucose ([ F]FDG), can yield inconclusive results. 16α-[ F]fluoro-17β-fluoroestradiol F]FES) be a powerful tool, providing high accuracy ER-positive disease. The aim this study was estimate the...
Therapeutic guidelines recommend prophylaxis against chemotherapy-induced (febrile) neutropenia (CIN/FN). Pegfilgrastim (Neulasta), biosimilar pegfilgrastim-jmdb (Fulphila), and pegfilgrastim with on-body injector (OBI; Neulasta Onpro) are options for CIN/FN prophylaxis. We aimed to simulate the cost-savings budget-neutral expanded access or anticancer treatment achieved through conversion from pegfilgrastim-OBI evaluate economic impact of FN-related hospitalization costs due...
Abstract BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are the recommended first-line standard-of-care (SOC) treatment for estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) patients. After progression on treatment, current clinical practice guidelines (NCCN, ESMO) recommend to sequence (in absence of visceral crisis) until there is no benefit after up 3 regimens, and subsequently...
3063 Background: ER status helps classify BC for the most appropriate treatment pathway. Biopsy (Bx) and immunohistochemical (IHC) are established procedures to determine in metastatic (mBC, i.e., first occurrence of metastases) recurrent (rBC, progression mBC). In some cases, accuracy Bx/IHC inform may be challenged (e.g. difficult access lesions; discordance within/across lesions due temporal heterogeneity; when a Bx fails obtain representative tissue). 16α-18F-fluoro-17β-fluoroestradiol...
Abstract Background: Mylan trastuzumab (MYL-1401O) is a biosimilar to (Herceptin®). A multicenter, double blind, randomized, phase III study (HERITAGE) compared the efficacy, safety, Pop PK and immunogenicity of MYL-1401O in patients with HER2-positive mBC. Patients were randomized 1:1 receive either or Herceptin®, combination taxane Q3W for 24 weeks followed by monotherapy until unacceptable toxicity, disease progression early discontinuation.Objectives: The objectives analysis compare...